Is there a future for tigecycline?

Intensive Care Medicine

Volumn 40, Issue 7, 2014, Pages 1039-1045

  Bassetti, Matteo ^a,c   Poulakou, Garyfallia ^b   Giamarellou, Helen ^b  

^a Servicio de Urologia   (Italy)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; METALLO BETA LACTAMASE; TIGECYCLINE; ANTIINFECTIVE AGENT; MINOCYCLINE;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; BACTEREMIA; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; CLINICAL PRACTICE; CRITICALLY ILL PATIENT; DIABETIC FOOT; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; INFECTION COMPLICATION; INTENSIVE CARE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; OBSERVATIONAL STUDY; PSEUDOMONAS INFECTION; RISK BENEFIT ANALYSIS; SEPTIC SHOCK; SKIN INFECTION; SOFT TISSUE INFECTION; SUPERINFECTION; SURVIVAL RATE; TRACHEOBRONCHITIS; VENTILATOR ASSOCIATED PNEUMONIA; WOUND INFECTION; ANALOGS AND DERIVATIVES; CRITICAL ILLNESS; FEMALE; INFECTION; MALE;

ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; FEMALE; HOSPITAL MORTALITY; HUMANS; INFECTION; MALE; MINOCYCLINE;

EID: 84903269473     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-014-3343-3     Document Type: Editorial

References (37)

1. FDA (2010) FDA drug safety communication: increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm. Accessed 28 April 2014
2. FDA (2013) FDA drug safety communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new boxed warning. http://www.fda.gov/drugs/drugsafety/ucm369580.htm. Accessed 5 May 2014
3. Yahav D, Lador A, Paul M, Leibovici L (2011) Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 66:1963-1971
4. Cai Y, Wang R, Liang B, Bai N, Liu Y (2011) Systematic review and metaanalysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 55:1162-1172
5. Tasina E, Haidich AB, Kokkali S, Arvanitidou M (2011) Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 11:834-844
6. McGovern PC, Wible M, El-Tahtawy A, Biswas P, Meyer RD (2013) All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials. Int J Antimicrob Agents 41:463-467
7. Vardakas KZ, Rafailidis PI, Falagas ME (2012) Effectiveness and safety of tigecycline: focus on use for approved indications. Clin Infect Dis 54:1672-1674
8. Prasad P, Sun J, Danner RL, Natanson C (2012) Excess deaths associated with tigecycline after approval based on non inferiority trials. Clin Infect Dis 54:1699-1709
9. Montravers P, Dupont H, Bedos J-P, Bret P, The Tigecycline Group (2014) Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting. Intensive Care Med. doi: 10.1007/s00134-014-3323-7
10. Bassetti M, Eckmann C, Bodmann KF, Dupont H, Heizmann WR, Montravers P, Guirao X, Capparella MR, Simoneau D, Sanchez Garcia M (2013) Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies. J Antimicrob Chemother 68(Suppl 2): 5-14
11. Kontopidou F, Giamarellou H, Katerelos P, Maragos A, Kioumis I, Trikka-Graphakos E, Valakis C, Maltezou HC, Group for the Study of KPC-producing Klebsiella pneumoniae infections in intensive care units (2014) Infections caused by carbapenemresistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. Clin Microbiol Infect 20:O117-O123
12. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F et al (2012) Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 55:943-950
13. Zarkotou O, Pournaras S, Altouvas G, Pitiriga V, Tziraki M, Mamali V, Themeli-Digalaki K, Tsakris A (2012) Comparative evaluation of tigecycline susceptibility testing methods for expanded-spectrum cephalosporin- and carbapenem-resistant gram-negative pathogens. J Clin Microbiol 50:3747-3750
14. Sheng WH, Wang JT, Li SY, Lin YC, Cheng A, Chen YC, Chang SC (2011) Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. Diagn Microbiol Infect Dis 70:380-386
15. Peck KR, Kim MJ, Choi JY, Kim HS, Kang CI, Cho YK, Park DW, Lee HJ, Lee MS, Ko KS (2012) In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant Acinetobacter baumannii, including colistin- or tigecycline-resistant isolates. J Med Microbiol 61:353-360
16. Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC (2013) Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother 57:1756-1762
17. De Pascale G, Montini L, Spanu T, Bernini V, Occhionero A, Grieco DL, Biancone M, De Santis P, Tanzarella ES, Cutuli SL et al (2013) High-dose tigecycline use in severe infections. Critical Care 17(Suppl 2):P80
18. Docobo-Pérez F, Nordmann P, Domínguez-Herrera J, López-Rojas R, Smani Y, Poirel L, Pachón J (2012) Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli. Int J Antimicrob Agents 39:251-254
19. Schafer JJ, Goff DA, Stevenson KB, Mangino JE (2007) Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 27:980-987 (Pubitemid 46986684)
20. Swoboda S, Ober M, Hainer C, Lichtenstern C, Seiler C, Wendt C, Hoppe-Tichy T, Büchler M, Weigand MA (2008) Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. J Antimicrob Chemother 61:729-733 (Pubitemid 351321153)
21. Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, Dukart G, Cooper A, Dartois N, Gandjini H, 309 Study Group et al (2008)Aphase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother 62(Suppl 1):i29-i40
22. Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E (2008) Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 46:567-570 (Pubitemid 351263497)
23. Gallagher JC, Rouse HM (2008) Tigecycline for the treatment of Acinetobacter infections: a case series. Ann Pharmacother 42:1188-1194
24. Curcio D, Fernández F, Vergara J, Vazquez W, Luna CM (2009) Late onset ventilator-associated pneumonia due to multidrug-resistant Acinetobacter spp.: experience with tigecycline. J Chemother 21:58-62
25. Gordon NC, Wareham DW (2009) A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 63:775-780
26. Poulakou G, Kontopidou FV, Paramythiotou E, Kompoti M, Katsiari M, Mainas E, Nicolaou C, Yphantis D, Antoniadou A, Trikka-Graphakos E et al (2009) Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. J Infect 58:273-284
27. Jamal W, Salama M, Dehrab N, Al Hashem G, Shahin M, Rotimi VO (2009) Role of tigecycline in the control of a carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit. J Hosp Infect 72:234-242
28. Freire AT, Melnyk V, Kim MJ, Datsenko O, Dzyublik O, Glumcher F, Chuang YC, Maroko RT, Dukart G, Cooper CA, 311 Study Group et al (2010) Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 68:140-151
29. Metan G, Alp E, Yildiz O, Percin D, Aygen B, Sumerkan B (2010) Clinical experience with tigecycline in the treatment of carbapenem-resistant Acinetobacter infections. J Chemother 22:110-114
30. Kuo SC, Wang FD, Fung CP, Chen LY, Chen SJ, Chiang MC, Hsu SF, Liu CY (2011) Clinical experience with tigecycline as treatment for serious infections in elderly and critically ill patients. J Microbiol Immunol Infect 44:45-51
31. Ye JJ, Lin HS, Kuo AJ, Leu HS, Chiang PC, Huang CT, Lee MH (2011) The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii. J Infect 63:351-361
32. Guner R, Hasanoglu I, Keske S, Kalem AK, Tasyaran MA (2011) Outcomes in patients infected with carbapenem-resistant Acinetobacter baumannii and treated with tigecycline alone or in combination therapy. Infection 39:515-518
33. Ku K, Pogue JM, Moshos J, Bheemreddy S, Wang Y, Bhargava A, Campbell M, Khandker N, Lephart PR, Chopra T et al (2012) Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections. Am J Infect Control 40:983-987
34. Moon SY, Peck KR, Chang HH, Kim SW, Heo ST, Son JS, Ryu SY, Moon C, Jung SI, Shin SY et al (2012) Clinical experience of tigecycline treatment in infections caused by extensively drug-resistant Acinetobacter spp. Microb Drug Resist 18:562-566
35. Kim NH, Hwang JH, Song KH, Choe PG, Kim ES, Park SW, Kim HB, Kim NJ, Park WB, Oh MD (2013) Tigecycline in carbapenem-resistant Acinetobacter baumannii bacteraemia: susceptibility and clinical outcome. Scand J Infect Dis 45:315-319
36. Lee YT, Tsao SM, Hsueh PR (2013) Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections. Eur J Clin Microbiol Infect Dis 32:1211-1220
37. Chuang YC, Cheng CY, Sheng WH, Sun HY, Wang JT, Chen YC, Chang SC (2014) Effectiveness of tigecycline-based versus colistin-based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis. BMC Infect Dis 14:102